Abstract: A method includes attaching semiconductor devices to an interposer structure, attaching the interposer structure to a first carrier substrate, attaching integrated passive devices to the first carrier substrate, forming an encapsulant over the semiconductor devices and the integrated passive devices, debonding the first carrier substrate, attaching the encapsulant and the semiconductor devices to a second carrier substrate, forming a first redistribution structure on the encapsulant, the interposer structure, and the integrated passive devices, wherein the first redistribution structure contacts the interposer structure and the integrated passive devices, and forming external connectors on the first redistribution structure.

Abstract: Described herein is a multilayered article (10) and methods of making and using such articles. The multilayered article (10) comprises: ?(a) a microsphere layer (11) comprising a plurality of microspheres disposed in a monolayer; ?(b) a bead bonding layer (12) comprising a first major surface and a second opposing major surface and the plurality of microspheres is partially embedded in the first major surface of the bead bonding layer, and comprises a thermoset polyurethane having a glass transition temperature of at least 35° C.; ?(c) a primer layer (14) disposed on the second major surface of the bead bonding layer wherein the primer layer comprises a copolymer of polyurea and polyurethane and wherein the primer layer is covalently attached to the bead bonding layer via urea linkages; and ?(d) an elastomeric layer (16) disposed on the primer layer opposite the bead bonding layer, wherein the elastomeric layer comprises a polyurethane thermoplastic elastomer.

Abstract: Diffusion for realistic scene generation includes obtaining a current set of agent state vectors and a map data of a geographic region, and iteratively, through multiple diffusion timesteps, updating the current set of agent state vectors. Iteratively updating includes processing, by a noise prediction model, the current set of agent state vectors, a current diffusion timestep of the plurality of diffusion timesteps, and the map data to obtain a noise prediction value, generating a mean using the noise prediction value, generating a distribution function according to the mean, sampling a revised set of agent state vectors from the distribution function, and replacing the current set of agent state vectors with the revised set of agent state vectors. The current set of agent state vectors are outputted.

Abstract: A luminaire includes a terminal block that receives power from a power source, a light source power supply electrically coupled to the terminal block and to a light source, a power converter electrically coupled to the terminal block and to a power over Ethernet injector, a camera coupled to the power over Ethernet injector, and a transceiver electrically coupled to the power converter. The power over Ethernet injector can supply power to and receive data from the camera. The transceiver is also coupled to the power over Ethernet injector and can communicate data to and receive data from the camera.

Abstract: The present application provides a method of treating castrate resistant prostate cancer in a patient, comprising administering to the patient a combination of afuresertib and CFG920, wherein the castrate resistant prostate cancer is also resistant to one or more standard of care treatments.

Abstract: A luminaire includes a terminal block that receives power from a power source, a light source power supply electrically coupled to the terminal block and to a light source, a power converter electrically coupled to the terminal block and to a power over Ethernet injector, a camera coupled to the power over Ethernet injector, and a transceiver electrically coupled to the power converter. The power over Ethernet injector can supply power to and receive data from the camera. The transceiver is also coupled to the power over Ethernet injector and can communicate data to and receive data from the camera.

Abstract: This disclosure is in the field of anti-Activin receptor IIB (ActRIIB) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse.

Abstract: This disclosure is in the field of anti-Activin receptor IIB (ActRIIB) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse.

Abstract: The present invention provides novel methods of inhibiting fibrosis, as well as methods of treating or inhibiting fibrotic disorders, using BMP9 and/or BMP10 antagonists. The present invention also provides methods of assessing whether a subject has or is at risk of developing a fibrotic disorder by detecting levels of BMP9 and/or BMP10. Further provided are methods of assessing the efficacy of a treatment regimen for treating a fibrotic disorder by detecting and comparing pre-treatment levels of BMP9 and BMP10 with post-treatment levels of BMP9 and BMP10.

Abstract: This disclosure is in the field of anti-Activin receptor IIB (ActRIIB) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse.

Abstract: This disclosure is in the field of anti-Activin receptor IIB (ActRIIB) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse.

Abstract: This disclosure is in the field of anti-Activin receptor IIB (ActRIIB) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse.

Abstract: The present invention provides novel methods of inhibiting fibrosis, as well as methods of treating or inhibiting fibrotic disorders, using BMP9 and/or BMP10 antagonists. The present invention also provides methods of assessing whether a subject has or is at risk of developing a fibrotic disorder by detecting levels of BMP9 and/or BMP10. Further provided are methods of assessing the efficacy of a treatment regimen for treating a fibrotic disorder by detecting and comparing pre-treatment levels of BMP9 and BMP10 with post-treatment levels of BMP9 and BMP10.

Abstract: This disclosure is in the field of anti-Activin receptor IIB (ActRIIB) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse.

Abstract: This disclosure is in the field of anti-Activin receptor IIB (ActRIIB) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse.

Abstract: The present invention relates to the use of modulators of the sclerostin:sclerostin-binding-partner interaction for the treatment, amelioration, and diagnosis of sclerostin-related disorders, e.g., osteoporosis and sclerosteosis, and sclerostin-related disorders, e.g., cancers and cardiovascular disorders. The invention also relates to the use of sclerostin-binding-partner mimetics for the treatment, amelioration, and diagnosis of sclerostin-related disorders. Assays for the identification of modulators of the sclerostin:sclerostin-binding-partner interaction, as well as the resulting signaling, are also provided.

Abstract: This disclosure is in the field of anti-Activin receptor IIB (ActRIIB) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse.

Abstract: The present invention relates to the use of modulators of the sclerostin: sclerostin-binding-partner interaction for the treatment, amelioration, and diagnosis of sclerostin-related disorders, e.g., osteoporosis and sclerosteosis, and sclerostin-related disorders, e.g., cancers and cardiovascular disorders. The invention also relates to the use of sclerostin-binding-partner mimetics for the treatment amelioration, and diagnosis of sclerostin-related disorders. Assays for the identification of modulators of the sclerostin: sclerostin-binding-partner interaction, as well as the resulting signaling, are also provided.

Abstract: The present invention relates to the use of TGF-? antagonists for the treatment, amelioration, and diagnosis of parathyroid-related disorders, e.g., HPT-JT, familial isolated primary hyperparathyroidism (FIPH), and hyperparathyroidism-jaw tumor (HPT-JT) syndrome, as well as its attendant complications. The present invention also relates to the use of modulators of HRPT2 and its related PAF1 complex for the treatment, amelioration, and diagnosis of TGF?-related disorders, e.g., pulmonary hypertension, cancer, hypertension, fibrosis, wound healing. Assays of the identification of modulators of HRPT2/PAF1 and SMAD/TGF? are also provided.